Abstract:BackgroundTo study nocturia in patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) after medical or placebo treatment.MethodsPatients with LUTS suggestive of BPH from several community clinics were included. Patients completed the International Prostate Symptom Score (I-PSS) questionnaire and a 3-day voiding diary. Urinalysis, prostate-specific antigen (PSA) measurement, and prostate ultrasonography were performed. Nocturnal polyuria (NP) was defined as a nocturnal urine fraction exceeding one third of the daily urine output in elderly men. A total of 148 outpatients were randomized to drug treatment (tamsulosin) or placebo treatment. After 8 weeks of treatment, they were re-evaluated using a 3-day voiding diary, PSA measurement, prostate volume (PV), I-PSS, etc.ResultsThe average I-PSS score was 20.3, storage symptom score was 11.7, voiding symptom score was 8.6, quality of life (QoL) score was 3.7, PV was 40.4 ± 19.4 ml, and nocturnal urine volume (NUV) was 845.7 ± 339.0 ml. The mean frequency of nocturia was 2.3 ± 1.1 per day, and 94% of the patients had a nocturia frequency of more than two times per day. Of these patients, 76.5% had NP. A significant correlation was found between NUV and the amount of water intake at night and 4 h before sleep (r = 0.419,P = 0.002; r = 0.302,P = 0.031). Eighty patients were randomized to drug treatment (tamsulosin) and 68 patients were randomized to placebo treatment. The I-PSS score was 16.8 ± 4.9 to 19.3 ± 5.0 (p = 0.002), the storage symptom score was 10.3 ± 3.4 to 10.7 ± 3.4 (p = 0.007), and the voiding symptom score was 7.5 ± 2.4 to 8.6 ± 2.3 (p = 0.003). The frequency of daytime urination was 7.5 ± 2.6 to 8.1 ± 2.6 (p = 0.002), maximum urine volume (ml) was 372.8 ± 103.3 to 302.8 ± 119.3 (p = 0.007), and morning urine volume (ml) was 280.5 ± 111.7 to 259.5 ± 100.7 (p = 0.003). However, the frequency of nocturia score was 2.8 ± 0.7 to 3.0 ± 0.6 (p = 0.306) and the nocturnal urine volume (ml) was 800.7 ± 323.0 to 845.7 ± 303.5 (p = 0.056), which did not change significantly. There were significant differences between the NP and non-NP groups in the duration of LUTS, first voided urine volume, daytime urination frequency, and the amount of water intake at night and 4 h before sleep.ConclusionsAmong the symptoms of LUTS, the improvement rates for nocturia were the lowest after medical treatment for BPH. The α-blockers did not improve nocturia, which was a common symptom accompanying LUTS suggestive of BPH. Our results showed that the prevalence of NP was 76.5% and that NP was significantly related to the amount of water intake during the evening and before sleep.Trial registrationISRCTN registry, Trial registration number (TRN): ISRCTN85509614, Date of registration: 30/10/2018. This trial was registered retrospectively.

Effect of Doxazosin Gastrointestinal Therapeutic System 4 Mg Vs Tamsulosin 0.2 Mg on Nocturia in Chinese Men with Lower Urinary Tract Symptoms: a Prospective, Multicenter, Randomized, Open, Parallel Study.

Efficacy and Tolerability of Doxazosin Gastro-Intestinal Therapeutic System Versus Tamsulosin in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia

Doxazosin Gastrointestinal Therapeutic System Versus Tamsulosin for the Treatment of Benign Prostatic Hyperplasia: a Study in Chinese Patients.

An Open, Comparative, Multicentre Clinical Study of Combined Oral Therapy with Sildenafil and Doxazosin GITS for Treating Chinese Patients with Erectile Dysfunction and Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.

Clinical Comparison of Selective and Non-Selective Alpha 1A-Adrenoceptor Antagonists for Bladder Outlet Obstruction Associated with Benign Prostatic Hyperplasia: Studies on Tamsulosin and Terazosin in Chinese Patients. the Chinese Tamsulosin Study Group.

Tamsulosin versus terazosin for benign prostatic hyperplasia: a systematic review.

Terazosin treatment in BPH/LUTS: a prospective, randomized, multicenter study

Tamsulosin Versus Terazosin for Benign Prostatic Hyperplasia: A Systematic Review

A multicenter prospective clinical study on the effectiveness and safety of terazosin in the treatment of Chinese benign prostatic hyperplasia patients

The evaluation of nocturia in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and the analysis of the curative effect after medical or placebo therapy for nocturia: a randomized placebo-controlled study

Comparative study of tamsulosin versus tadalafil in benign prostatic hyperplasia patients with lower urinary tract symptoms. A prospective randomized study

A Systematic Review and Meta-Analysis of the Efficacy and Safety of Tamsulosin Plus Tadalafil Compared With Tamsulosin Alone in Treating Males With Lower Urinary Tract Symptoms Secondary to Benign Prostrate Hyperplasia

Combination of Tamsulosin and Tolterodine Alleviates Refractory Lower Urinary Tract Symptoms in Male Patients

Pharmacoeconomic Evaluation of Tamsulosin Hydrochloride Sustained-release Capsules in the Treatment of Benign Prostatic Hyperplasia

Efficacy and Safety of Long-Term Administration of Tamsulosin Hydrochloride in Patients with LUTS Suggestive of BPH

A Comparative Study on the Safety and Efficacy of Tamsulosin and Alfuzosin in the Management of Symptomatic Benign Prostatic Hyperplasia: A Randomized Controlled Clinical Trial

The safety and efficacy of doxazosin in medical expulsion therapy for distal ureteric calculi: A meta-analysis

Silodosin is Effective for Treatment of LUTS in Men with BPH: a Systematic Review

Effects of Tamsulosin Combined with Solifenacin on Lower Urinary Tract Symptoms: Evidence from a Systematic Review, Meta-Analysis, and Trial Sequential Analysis of Randomized Controlled Trials.

Efficacy Of Combined Amlodipine/Terazosin Therapy In Male Hypertensive Patients With Lower Urinary Tract Symptoms: A Randomized, Double-Blind Clinical Trial

Effect of different alpha-receptor antagonists on metabolic parameters: a head-to-head comparison